Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.91 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522620 | 1.00 | LTA4H (0.91) | LTA4HL3MBTL1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20238887 | 0.95 | LTA4H (1.00) | LTA4HL3MBTL1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20238889 | 0.95 | LTA4H (1.00) | LTA4HL3MBTL1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL21690025 | 0.90 | LTA4H (0.75) | LTA4HL3MBTL1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10882882 | 0.88 | LTA4H (0.72) | LTA4HL3MBTL1MAPTHTT | |
| SCHEMBL10879524 | 0.88 | LTA4H (0.72) | LTA4HL3MBTL1MAPTHTT | |
| SCHEMBL24032787 | 0.87 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3503717 | 0.87 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3503714 | 0.87 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29398310 | 0.87 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252728-B2 | Systems and methods for measuring liver enzyme levels in blood | NOVA BIOMEDICAL CORPORATION (US) | 2025-03-18 | — | — | US | claimed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4594336-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-20250171824-A1 | Analyte Sensor Strip for Measuring Liver Enzyme Levels | NOVA BIOMEDICAL CORPORATION | 2025-05-29 | — | — | US | disclosed |
| US-12252728-B2 | Systems and methods for measuring liver enzyme levels in blood | NOVA BIOMEDICAL CORPORATION (US) | 2025-03-18 | — | — | US | disclosed |
| CN-114096250-B | Therapies for erythropoiesis protoporphyria (EPP) and X-linked protoporphyria (XLP) | 匹兹堡大学 联邦高等教育系统 | 2025-01-14 | — | — | CN | disclosed |
| CN-119306640-A | Gamma-glutamyl transpeptidase detection substrate and preparation method and application thereof | 英科新创(厦门)科技股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| WO-2024073605-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC. (JP) | 2024-04-04 | — | — | WO | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| US-5116730-A | AMINO ACID SUBSTITUTED 4-AMINOPHENAZONES FOR MEASURING ENZYME ACTIVITY | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1992-05-26 | — | — | US | disclosed |
| US-5081259-A | Novel amino acid substituted 4-aminophenazones for measuring enzyme activity | ABBOTT LABORATORIES (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0346870-A2 | Novel amino acid substituted 4-aminophenazones for measuring enzyme activity | THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4801721-A | Stereospecific synthesis of carboxyalkyl peptides | RYAN JAMES W (US) | 1989-01-31 | — | — | US | disclosed |
| US-4603107-A | SIMUTANEOUSLY REACTING WITH GLUTAMYLARYLAMIDE, THEN OXIDIZER AND COUPLING AGENT TO GIVE COLORED COMPOUND | BOEHRINGER MANNHEIM GMBH (DE) | 1986-07-29 | — | — | US | disclosed |
| EP-0103823-A2 | Method and reagent for the determination of gamma-glutamyltransferase | Roche Diagnostics GmbH (DE) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | ABCC3, ABCC2, ABCB7 | LTA4H 2245/4885L3MBTL1 980/4885SLC1A3 871/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | LTA4H 3838/4885L3MBTL1 250/4885SLC1A3 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.